NewsBite

Chipping away at the mysteries of a beautiful mind

Australia’s Nick Opie is at the vanguard of technology that reads brains. Will the Synchron co-founder beat the likes of Elon Musk as the first to release this life-changing tech? It’s likely.

Sychron co-founder and chief technology officer Nicholas Opie. Picture: Arsineh Houspian.
Sychron co-founder and chief technology officer Nicholas Opie. Picture: Arsineh Houspian.

It is rare to find yourself in the company of billionaires – let alone beat one of them at

their own game – but it is now an everyday reality for Melbourne biomedical engineer

Professor Nick Opie. 

Opie is at the forefront of developing computer chips for people’s brains, connecting

the mind directly with a computer, and sparking a race that has Bill Gates, Jeff Bezos

and Elon Musk jostling for pole position.

Scientists say the technology has the potential to overcome a range of disabilities

and neurological disorders – from restoring sight and movement lost from paralysis

to treating Parkinson’s disease, epilepsy and depression.

Whether it sounds fantastic or frightening, the ability to read and translate the brain’s

electrical codes and signals is creating the foundations for a new multibillion-dollar

global industry.

Synchron, the company that Opie co-founded and is backed by Gates and Bezos,

likens it to a bluetooth for the brain. It offers patients with paralysis a hands-free

experience to regain independence.

While Musk and his high-profile antics – ranging from space, Twitter (now X) and

beyond – has thrust the technology into the spotlight, it is at Synchron where the

rubber has actually hit the road.

Synchron was the world’s first company to be granted approval from the US Food

and Drug Administration to begin clinical trials on a permanent computer-brain

implant, and enrolled its first patient last year, beating Musk’s Neuralink to that

milestone. 

So how does it work? Synchron uses a stent-like implant to line blood vessels, and

there are almost 650km of them in each brain, with electrodes or sensors to

record brain activity and convert that into a digital signal to stream thought into an

iPhone or other smart device.

This allows people with paralysis to perform everyday tasks such as online shopping

and banking, sending text messages or simply turning off a bedroom light.

“We can translate these (brain) signals into switches or clicks,” Opie explains. 

“If a patient really wants to use a computer, for example, we can offer them a mouse

click and they can start using the mouse as they would have before they were

paralysed.”

Crucially, the stent-like design avoids the needs for open brain surgery.

But Opie says brain chips were not his first thought when he decided to use his

engineering skills to help restore various human functions.

He began his career working on the bionic eye at the University of Melbourne where

he met Synchron’s co-founder and chief executive, Associate Professor Tom Oxley.

Professor Nick Opie’s Synchron was the first company to be granted approval by the FDA to run clinical trials on a permanent computer-brain implant.
Professor Nick Opie’s Synchron was the first company to be granted approval by the FDA to run clinical trials on a permanent computer-brain implant.

“When I started off many years ago – I’m an engineer, so I like the tech and the

gadgets – I was thinking, ‘oh, let’s make all these amazing arms and exoskeletons,

robotics legs, etc’,” Opie says.

“Don’t get me wrong, I’m sure that’s still on the table. But we have found we can

provide a huge amount of value and benefit to these patients with just simple stuff

that perhaps I didn’t appreciate the value of when starting this journey.”

So far, Synchron’s technology has allowed a father, who has suffered paralysis, to

turn off a TV when he has decided his daughters have had enough screen time.

Another paralysis patient was able to chat with Opie about the footy over WhatsApp.

“All the patients are doing really well,” Opie says. 

“I think one of the big things that we've done recently was start connecting to the

folks in the US who are completely locked in; so they're bed bound, assisted

breathing, assisted eating, all those sorts of things. They have a lot of difficulty

communicating or they can't communicate – even with eye trackers or other

technology that’s available, they just can’t use it. So what we've been able to do is

hooking them up to an iPhone. 

“There’s a screen that shows what they’re doing on the iPhone, you can put the

iPhone in front of them and they can then do patient reporting so they can send

messages using our system to their carers. The patients can send messages even if

the carers aren't there, creating a huge benefit to them.”

On this score, Synchron has continued a tradition set by Australian industrialist Paul

Murray Trainor, who founded The Nucleus Group in 1965. Nucleus was responsible

for the Cochlear bionic ear, the first cardiac pacemakers, cardiac defibrillators and

dozens of medical technologies in use today, with its staff becoming successful in

their own right forming companies including sleep apnoea giant ResMed.

Opie and his colleagues are now excited about potentially using its implant to

stimulate different areas of the brain to alleviate other conditions.

For instance, if part of the brain is damaged by a stroke, it is like a blockage on

Sydney’s Eastern Distributor, whereby motorists are diverted onto side streets and

other roads to reach their destination.

In the brain, neuroscientists call this neuroplasticity, meaning other parts of the organ

can step up and take over the functions of others that have been damaged through

disease or injury. 

“At the moment, we are just focusing on paralysis, but one example of how we could

use it for epilepsy is a seizure recording diary … an implanted device that continually

monitors your brain health and can provide physicians with when you’re having

seizures and how long they last,” Opie says.

“An issue with a lot of seizure diaries at the moment is people can’t remember when

they had one so they might not be reporting them back to clinicians who then use

that information to prescribe medicine.

“Once you can record seizures, you could then start predicting when they’re going to

occur. You can see the brain activity change before it turns into a large seizure …

and, if you get in early enough, you can … provide stimulation to a different part of

the brain to stop the seizure from happening. That’s the long-term goal of a closed

loop neuromodulation.”

Similarly with Parkinson’s disease – if you target a specific area of the brain and

stimulate it, it can stop tremors.

But the brain, the seat of consciousness, remains one of the body’s most mysterious

organs. There are conditions in which chips can alleviate, but scientists and doctors

are yet to understand how it works.

“It’s an interesting time in medicine with the technology sort of giving us the answers

to questions we haven’t really thought of yet,” Opie says.

“With depression, how that works, everyone is still looking at it. You put stimulation in

and it seems to work for a lot of people but it’s still unclear on the physiological

pathways of why that’s occurring.”

Synchron has raised $220m to date to develop the technology. Early funding

came from the US Defense Advanced Research Projects Agency, which has a

significant brain program. Other recent investors include US venture capital group

ARCH Venture Partners, Microsoft founder Bill Gates’ private venture fund Gates

Frontier, and Amazon founder Jeff Bezos’ family office Bezos Expeditions.

The List: Top 100 Innovators 2023 launches online and in The Australian on Friday, September 15. It is a celebration of Australia’s boundary pushers and fierce innovators.

Read related topics:Elon Musk
Jared Lynch
Jared LynchTechnology Editor

Jared Lynch is The Australian’s Technology Editor, with a career spanning two decades. Jared is based in Melbourne and has extensive experience in markets, start-ups, media and corporate affairs. His work has gained recognition as a finalist in the Walkley and Quill awards. Previously, he worked at The Australian Financial Review, The Sydney Morning Herald and The Age.

Add your comment to this story

To join the conversation, please Don't have an account? Register

Join the conversation, you are commenting as Logout

Original URL: https://www.theaustralian.com.au/business/chipping-away-at-the-mysteries-of-a-beautiful-mind/news-story/e95e9d26865b244c437e330126a476c2